PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsUnmet Needs in LDL-C Lowering: When Statins Won't Do!PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabCardiovascular risk stratification in familial hypercholesterolaemiaClinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reductionPCSK9 inhibition: the way forward in the treatment of dyslipidemiaPCSK9 and triglyceride-rich lipoprotein metabolismProfile of evolocumab and its potential in the treatment of hyperlipidemiaDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersPCSK9 inhibitors in the prevention of cardiovascular diseaseThe year in cardiology 2015: preventionDynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise trainingPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraRetargeting the management of hypercholesterolemia - focus on evolocumabEvolocumabNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilAntibodies to watch in 2015PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaVery low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to dateLDL-Cholesterol: Standards of Treatment 2016: A German Perspective.US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry.Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaPCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).PCSK9 antibodies for the treatment of hypercholesterolemiaPCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsEncapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and ManagementThe Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-AnalysisSystematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.
P2860
Q26741078-52C5F163-35F2-4D23-9320-2E6754FE2FBCQ26741705-C9C97647-5C57-4D81-88D7-B946F6918054Q26747776-F6717A35-AF8D-4D2F-95D1-2D0B44900B44Q26749104-E23A2674-F289-4A1C-9C51-4D991578764FQ26752950-1579E5D3-3A1A-4C0B-A06D-ED308D26A19BQ26784482-038DA99E-5E97-4020-90E3-297A012ED3E2Q26796287-99B76960-2B27-41EE-A92D-E6DB689C5522Q27004235-3C4FF567-4CF7-4A39-BA75-02BE12BD7F74Q28070296-3BA768C5-CC1C-4770-A827-2BD6698BAC16Q28071452-3E7319EA-5E59-425D-AD67-64A510A17F6BQ28072221-9F8469F7-E17F-4475-95CA-86C08A0CFFCCQ28073180-A5B37AF7-49BC-4FDC-90A6-37FE9CB38D3DQ28073656-EF12F313-5208-4781-9E3E-5865985F264BQ28077289-A8E2A568-2BF8-4D3C-A178-0E5B39E20CE9Q28078902-6E7260A8-DE2D-4011-B040-110700AFAD0BQ28084156-CBCC0C35-53E3-485B-8058-A571CFBAE181Q28253501-A0FB573C-3B04-4149-9BEF-D2CEB00E97B6Q28275648-5BBE8B2B-480E-4343-A739-ED6C3B8C7855Q30244599-81FF0554-B2F1-428B-A4CF-5F3B8F0E2338Q30248925-B1DE69AB-2249-4F5A-8CA3-47B2CADED27AQ31133478-AD57A85A-80BD-42BD-A12D-4AA656286985Q31161044-AECEA612-73F9-42E1-B053-355F4F08B7E4Q33599961-D2AECF7F-DF0B-41ED-8CC8-04C4532F5CBEQ33670893-FF873FEC-6B2D-41BB-8EF1-50075DD826A4Q33728343-CA5955BA-FAFA-4280-B595-51FF48379B04Q33904455-F465FE8D-EF87-42A0-8620-A3AD7AEA5DB0Q34458693-5F299A08-5ED7-4A57-B2E3-D5130B470701Q34774969-AD135BD5-549F-40FC-A759-ED6054E82E0BQ35262593-B74C61D8-1855-4179-8570-522A05278981Q35664577-CF75BAF4-6007-4448-92B1-A0A34A6FBA46Q35671077-8C1CBCF7-A7E1-483A-9701-E9AD0BD45707Q35723422-32750E99-8F8C-4645-80C6-9CE20AAB0B33Q35756629-FFE66C13-5231-4514-8185-0571D5C81A46Q35868554-4EB612B4-99B2-4ED4-9914-EBC4E6C8871CQ36091331-C2E1875B-9DB3-4EF4-8E79-A3E75C3BC8B0Q36130225-E454B736-233D-43B6-B061-97E5B23CFCF0Q36366067-361089B1-C639-4B83-9768-B8A7B68D0E99Q36385726-4DE213A7-488A-42F2-AF90-F2441BD57498Q36411986-3003861B-F04F-4944-A9CC-AA3DFBF4E3EDQ36480595-40715F68-E92C-4308-BE48-F345B70B9AFA
P2860
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
PCSK9 inhibition with evolocum ...... ind, placebo-controlled trial.
@en
PCSK9 inhibition with evolocum ...... ind, placebo-controlled trial.
@nl
type
label
PCSK9 inhibition with evolocum ...... ind, placebo-controlled trial.
@en
PCSK9 inhibition with evolocum ...... ind, placebo-controlled trial.
@nl
prefLabel
PCSK9 inhibition with evolocum ...... ind, placebo-controlled trial.
@en
PCSK9 inhibition with evolocum ...... ind, placebo-controlled trial.
@nl
P2093
P1433
P1476
PCSK9 inhibition with evolocum ...... ind, placebo-controlled trial.
@en
P2093
Anders G Olsson
Bertrand Cariou
Daniel Gaudet
David Sullivan
Evan A Stein
Fernando Civeira
Frederick J Raal
G Kees Hovingh
Gisle Langslet
Ian Bridges
P304
P356
10.1016/S0140-6736(14)61399-4
P407
P577
2014-10-01T00:00:00Z